Our Life Sciences and Healthcare team work with some of the largest pharmaceutical, biotechnology, and medical device companies and healthcare providers in the world to a diverse collective of small-to-medium-sized start-up enterprises ready to upscale their business, and many companies in between. We guide ambitious global clients within these dynamic and innovative industries through the maze of connected legal, commercial, and regulatory challenges.

We devise transformative business transactions for our life sciences and healthcare clients through strategic partnering collaborations, raising or placing capital or completing game-changing M&A transactions, and act on contentious matters such as patent litigation, product liability, and disputes with regulators.

Our Life Sciences and Healthcare team protects the value of our clients’ businesses enabling global expansion by providing practical, commercial recommendations on their complex regulatory, competition, compliance, and data protection requirements.

Whether our clients are in the pharmaceutical, biotechnology, medical device (including IVD’s), digital health, or healthcare industry, companies and investors value our ability to provide seamless legal and regulatory advice across Europe, the Middle East, and Asia. Through working alongside our partner network, we can ensure global coverage, including the key US market.

Areas of focus

Experience

Advising gene therapy company AlveoGene on its complex spinout and launch investment

We have advised AlveoGene, a new UK gene therapy company on its complex spinout from the Gene Therapy Consortium of Imperial College and the Universities of Oxford and Edinburgh focusing on rare respiratory diseases, as well as on its seed round investment.

Press release

Colin McCall

Ross McNaughton

Bella Thornton-Clark

See full team Hide full team

Apollo Therapeutics closes $226.5 million series C financing

We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.

Press release

Andrew Edge

Howard Palmer

Oli Denne

See full team Hide full team

Successful financing and add on acquisitions for Oberberg Group

Oberberg Group on the successful refinancing of its existing credit lines. The new financing also served several add-on acquisitions. This included the internationally renowned private clinic Jägerwinkel am Tegernsee, which is expanding the treatment spectrum of the Group with its range of integrative holistic psychosomatics with a focus on interdisciplinary pain therapy. In addition, Panorama Fachklinik, an acute hospital for psychosomatics, and Privatklinik Hubertus im Allgäu, a specialist hospital for psychosomatics, psychotherapy and naturopathy, were acquired.

Press release

Ulf Gosejacob

Sabine Schomaker

Dr. Michael Beyer, Dipl.-Volkswirt

Dr. Oliver Kirschner

Christopher Peine

See full team Hide full team

Babylon Health continues to invest in digital healthcare with largest European and US fundraising

Babylon Health, a UK-based digital health subscription provider, on its USD550m fundraising to support expansion into the US and Asia. This is the largest ever fundraising in the European or US digital health sector and values Babylon at over USD2bn. Investors included PIF, ERGO Fund, Kinnevik and Vostok New Ventures.

Press release

Josef Fuss

Graham Samuel-Gibbon

Steadfast Capital Fund IV on the acquisition of a majority stake in Söhngen Group

Steadfast Capital Fund IV on the acquisition of a majority stake in Söhngen Group. The transaction included both W. Söhngen GmbH based in Taunusstein (Hesse) and Silva GmbH based in Mainhausen (Hesse). The parties have agreed not to disclose the purchase price. The majority acquisition aims to support further growth of the Söhngen Group with its internationally recognised brands and premium products in the market for first aid and emergency medical products both organically and through acquisitions. We also advised on the financing of the acquisition.

Press release

Maria Weiers

Ulf Gosejacob

Dr. Marcel Leines

Daniel Mursa, LL.M. (Köln/Paris I)

Johannes Simon, LL.M. (Durham)

Dr. Tim Eickmanns

Dr. Jan Kern

Dr. Andrea Sautter

Sebastian Rünz, LL.M. (Toronto)

See full team Hide full team

NORD Holding on the acquisition of Zentrum Gesundheit Group

NORD Holding, a leading private equity house, on the acquisition of the majority interest in Zentrum Gesundheit Group, a leading German group of ophthalmic surgery and diagnostic centres, from Waterland Private Equity. NORD Holding, together with the management and medical team, acquired a stake as a new partner and majority shareholder. In this deal the Taylor Wessing team again demonstrated its interdisciplinary expertise in the areas of healthcare M&A, regulatory and acquisition financing.

Press release

Dr. Michael Beyer, Dipl.-Volkswirt

Dr. Vanessa Christin Vollmar

Eva-Maria Bendig-Siepker, LL.M. (Medizinrecht)

Dr. Lars Hagen

Dr. Marco Hartmann-Rüppel, Dipl.-Volkswirt

Dr. Michael Brüggemann

Thanos Rammos, LL.M.

Dr. Daniel Tietjen

See full team Hide full team

More Show less

Resources

Environmental, social & governance

Environmental, Social, and Governance (ESG) issues are not just checkboxes to be ticked; they represent critical demands and opportunities that will shape the future of businesses and communities. At Taylor Wessing, we are committed to helping you go beyond mere compliance, focusing on building more resilient and sustainable economies for a brighter future.

Start your ESG journey

Our team

Please feel free to contact any of the people listed here for more information about our capabilities and their expertise in the Life Sciences & Healthcare sector in your jurisdiction. You can also search for a particular individual or see the whole team by using our people finder.

Prev. Next